Eurasian Journal of Medicine and Oncology

Scope & Guideline

Championing Research for a Healthier Future

Introduction

Welcome to your portal for understanding Eurasian Journal of Medicine and Oncology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherKARE PUBL
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationEURASIAN J MED ONCOL / Eurasian J. Med. Oncol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGoztepe Mah. Fahrettin Kerim Gokay Caddesi. No: 200/A D:2 Cemenzar - Kadkoy, ISTANBUL 34720, Turkiye

Aims and Scopes

The Eurasian Journal of Medicine and Oncology focuses on advancing the understanding of cancer and related diseases through innovative research and clinical studies. It encompasses a wide range of topics, emphasizing the integration of clinical practice and laboratory research to improve patient outcomes.
  1. Cancer Biology and Mechanisms:
    The journal publishes research exploring the underlying biological mechanisms of various cancers, including molecular and genetic studies that elucidate tumor behavior and treatment responses.
  2. Clinical Oncology and Treatment Strategies:
    It emphasizes studies on clinical practices, including novel treatment protocols, chemotherapy regimens, and the implementation of immunotherapy in cancer management.
  3. Epidemiology and Public Health:
    The journal addresses the epidemiological aspects of cancer, focusing on risk factors, demographics, and healthcare delivery systems, particularly in Eurasian populations.
  4. Innovative Technologies in Oncology:
    Research on the application of advanced technologies, including artificial intelligence and machine learning in diagnostics and therapeutic approaches, is a key area of focus.
  5. Patient Care and Quality of Life:
    Studies related to patient management, quality of life assessments, and supportive care strategies are also prominent, reflecting the journal's commitment to holistic cancer care.
The journal has recently highlighted several emerging themes that reflect current trends in oncology research. These themes showcase innovative approaches and a growing interest in areas that promise to advance the field significantly.
  1. Integration of Artificial Intelligence in Oncology:
    There is a rising trend in the application of artificial intelligence and machine learning to enhance diagnostic accuracy and treatment personalization in cancer care.
  2. Immunotherapy and Biomarkers:
    Research focusing on immunotherapy, particularly the identification of biomarkers for patient selection and treatment efficacy, has gained momentum, indicating a shift towards more targeted therapies.
  3. Personalized Medicine:
    The exploration of personalized treatment approaches based on genetic profiling and individual patient characteristics is becoming increasingly prominent, reflecting a broader trend in oncology.
  4. Multidisciplinary Approaches to Cancer Care:
    There is a growing emphasis on multidisciplinary treatment strategies that involve collaboration among various specialties to optimize patient outcomes.
  5. Longitudinal Studies and Real-World Evidence:
    The journal is increasingly publishing longitudinal studies that provide real-world evidence of treatment effectiveness and patient outcomes, reflecting a shift towards practical and applicable research.

Declining or Waning

While certain areas of research remain central to the journal's mission, others appear to be declining in prominence based on recent publications. This shift may reflect changes in the research landscape or evolving priorities within oncology.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in publications centered solely on traditional chemotherapy approaches, suggesting a shift towards more innovative and personalized treatment modalities.
  2. Basic Science without Clinical Application:
    Research that focuses exclusively on basic science without a clear translational aspect to clinical applications has become less frequent, indicating a preference for studies that bridge laboratory findings with patient outcomes.
  3. Single-Agent Studies:
    The journal has seen fewer studies examining the effects of single-agent therapies as the focus increasingly turns to combination therapies and personalized medicine strategies.
  4. General Cancer Awareness Campaigns:
    There is a decline in articles solely focused on general cancer awareness and education campaigns, possibly reflecting a more research-oriented approach in recent publications.
  5. Non-Oncological Conditions:
    Research related to non-oncological conditions or co-morbidities, while still important, has decreased in frequency, with a more concentrated focus on oncology-specific studies.

Similar Journals

World Journal of Clinical Oncology

Fostering Collaboration in the Fight Against Cancer
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

ONCOLOGIST

Empowering discoveries in oncology and beyond.
Publisher: OXFORD UNIV PRESSISSN: 1083-7159Frequency: 12 issues/year

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

Onkologie

Exploring Innovations in Cancer Care and Research.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

Oncology in Clinical Practice

Transforming Patient Care with Cutting-Edge Research
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

Oncology Research and Treatment

Uniting researchers to combat cancer effectively.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

Bladder Cancer

Exploring innovative treatments for bladder cancer.
Publisher: IOS PRESSISSN: 2352-3727Frequency: 4 issues/year

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

Asia-Pacific Journal of Clinical Oncology

Elevating clinical practices with cutting-edge research.
Publisher: WILEYISSN: 1743-7555Frequency: 6 issues/year

Asia-Pacific Journal of Clinical Oncology is an essential publication within the field of medical oncology, dedicated to advancing the understanding and treatment of cancer through rigorous research and innovative clinical practices. Published by WILEY, this journal has established itself as a significant resource for researchers, healthcare professionals, and students interested in the latest findings across the Asia-Pacific region and beyond. With a respectable impact factor and categorized within the Q2 and Q3 quartiles of Medicine (miscellaneous) and Oncology respectively, the journal aims to disseminate knowledge on diverse aspects of clinical oncology, promoting the improvement of patient care and treatment outcomes. The Asia-Pacific Journal of Clinical Oncology, operating from the United Kingdom, invites contributions that highlight significant findings and advancements in oncology, making it a crucial platform for collaboration and knowledge sharing in this vital field of medicine.

Gynecologic Oncology Reports

Transforming research into impactful clinical practices.
Publisher: ELSEVIER SCIENCE INCISSN: 2352-5789Frequency: 4 issues/year

Gynecologic Oncology Reports is a pivotal interdisciplinary journal published by Elsevier Science Inc. that has been dedicated to advancing the understanding of women's health since its inception in 2014. This Open Access journal, available to a global audience, facilitates the dissemination of high-quality research in the fields of gynecology and oncology, allowing for the free exchange of knowledge and fostering collaboration among researchers, clinicians, and students. With an impact factor reflective of its commitment to clinical relevance, Gynecologic Oncology Reports holds a Q3 ranking in both obstetrics and gynecology as well as oncology categories, contributing to its visibility and the prestige of published work. Situated in the Netherlands and operating within an open-access framework, it ensures that critical findings and advancements reach a broad readership. The journal serves as a vital resource for those aiming to stay at the forefront of gynecologic oncology, promoting improved patient outcomes through cutting-edge research. As it converges towards its 10th anniversary in 2024, Gynecologic Oncology Reports continues to be an essential platform for scholarly communication in this important field.

BULLETIN DU CANCER

Innovative insights shaping the future of oncology.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

Tumori Journal

Empowering Oncology Through Innovative Discoveries.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.